PDCD1 and neoplasm: While both tumor types were unresponsive to anti‐PD‐1 or anti‐RANKL monotherapies, the addition of anti‐RANKL to anti‐PD‐1 significantly suppressed established tumor growth (Figure 3a, b), consistent with the previous report15 using rat IgG2a hybridoma antibodies.